RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Bladerunner - you touched on several recurring thoughts I have about Cortex.

It still amazes me that sheer size of the markets that Ampakines may eventually be approved for, combined with the lean pipelines of many BPs, doesn't result in competitive bidding for Cortex's deals and doesn't result in much higher valuations being discussed for those deals.

Perhaps both of those situations have already changed unbeknown to us yet, or will have changed when the deal making process finally plays out and shows competitive interest driving the deal prices up.

But for now it seems that no one is expecting any kind of eyebrow raising deal for either CX717 or the high impacts.

It will be ironic if Cortex gets a better deal for CX717 now vs. 15 months ago - but a year plus of patent life has also been lost. The eventual lost revenue cost for that year of patent life could be huge.

Cortex's stock price misadventures have allowed me to now hold many more shares of COR than I ever expected to hold - and I'm guessing that's true for a lot of the readers/posters on this board.

Those who followed the company closely last year had several good opportunities to sell COR knowing it had a good chance of dropping lower.

Then came the CC where Dr. Stoll showed clear confidence that the FDA finding was caused by the fixative, and that provided a golden opportunity for those closely watching COR to jump back in.

So... the irony of the FDA hold and dosage restrictions possibly helping Cortex with a much higher deal valuation also extends to all of the COR longs who now hold more shares than before and at lower average prices.

Both life and biotech investing are a series of improbable twists and turns.